AFP and neoplasm: In the absence of guiding evidence, immunosuppression should be selected based on a personalized approach that takes into account several factors, including patient conditions, the Model for End-stage Liver Disease (MELD) score, tumor burden, response after locoregional treatment according to the modified Response Evaluation Criteria in Solid Tumors (mRECIST), alpha-fetoprotein (AFP) levels, and the time spent on the waiting list before LT [16, 17].